Newsletter Tool

To view this email as a web page, click here

Today's Rundown

GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D site
Surges in hospitals led to poorer COVID-19 outcomes, study finds. Should we prepare differently for the next pandemic?
Pfizer taps HIV, hep C antiviral research for COVID-19 pill trial
CureVac's COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant
Kaufman Hall: Nearly 40% of hospitals may face negative margins this year even with smooth vaccine rollout
Healthcare roundup: CMS extending Healthcare.gov special enrollment period
Biopharma roundup: India to block AZ vaccine exports; Germany backs off extended Easter lockdown
National Resilience, months after launching with $800M, snags Sanofi biomanufacturing plant

Featured Story

GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D site

By Arlene Weintraub

GlaxoSmithKline has fired company veteran Moncef Slaoui from the board of its majority owned Galvani Bioelectronics, following allegations from a GSK employee of sexual harassment. GSK CEO Emma Walmsley told employees she is "shocked and angry" and that the company will rename its Slaoui Center for Vaccines Research.

Surges in hospitals led to poorer COVID-19 outcomes, study finds. Should we prepare differently for the next pandemic?

By Tina Reed

Researchers from the University of California, San Francisco teamed with care coordination software company Careport Health to look at whether surges of patients at hospitals impacted patient outcomes. As it turned out, there was a clear difference.

Pfizer taps HIV, hep C antiviral research for COVID-19 pill trial

By Ben Adams

Pfizer has already seen major success with its BioNTech-partnered COVID-19 vaccine, but, now, the Big Pharma is hoping to add to the arsenal with a pandemic pill using old antiviral technology.

CureVac's COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant

By Angus Liu

Emerging coronavirus variants threaten the potency of existing COVID-19 vaccines, sending their manufacturers on a quest to develop booster shots. CureVac, which is in late-stage testing of its mRNA shot, now has mouse data showing its product could stave off one aggressive COVID-19 variant first identified in South Africa.

Kaufman Hall: Nearly 40% of hospitals may face negative margins this year even with smooth vaccine rollout

By Robert King

An analysis from Kaufman Hall found nearly 40% of hospitals may face negative operating margins this year even after a smooth rollout of the COVID-19 vaccine.

Healthcare roundup: CMS extending Healthcare.gov special enrollment period

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: India to block AZ vaccine exports; Germany backs off extended Easter lockdown

By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

With an urgent need for COVID vaccines, India will block exports of the AstraZeneca shot from the Serum Institute. German chancellor Angela Merkel adjusted her decision to lock the country down for five days around Easter. GSK has cut ties with former Operation Warp Speed co-leader Moncef Slaoui over a sexual harassment allegation. And more headlines.

National Resilience, months after launching with $800M, snags Sanofi biomanufacturing plant

By Fraiser Kansteiner

Resilience picked up two commercial production facilities in Canada and the U.S., lifting its North American footprint to more than 750,000 square feet. The expansion comes just months after Resilience's November 2020 launch, when the company unveiled its mission to build "the world's most advanced biopharmaceutical manufacturing ecosystem."

COVID-19 Tracker